United States - English - NLM (National Library of Medicine)

padagis us llc - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), opium (unii: 37m3mz001l) (opium - unii:37m3mz001l) - atropa belladonna 16.2 mg - belladonna and opium suppositories are indicated for the management of ureteral spasm pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve belladonna and opium suppositories for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: risk summary prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome. there are no available data with belladonna and opium suppositories in pregnant women to inform a drug associated risk for major birth defects and miscarriage. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated bac

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), opium (unii: 37m3mz001l) (opium - unii:37m3mz001l) - belladonna and opium suppositories are indicated for the management of ureteral spasm pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1) ], reserve belladonna and opium suppositories for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: risk summary prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome. there are no available data with belladonna and opium suppositories in pregnant women to inform a drug associated risk for major birth defects and miscarriage. clinical considerations fetal/neonatal adverse reactions prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. the onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [see warnings and precautions (5.3) ]. belladonna refers to plant alkaloids that contain anticholinergic agents such as atropine. atropine used in human pregnancies has not been associated with birth defects or adverse fetal effects although the drug readily crosses the placenta. use during pregnancy may increase risk of respiratory abnormalities, hypospadias, and eye or ear malformations but causal relationship is unclear. the collaborative perinatal project found no relationship between first trimester use of atropine and birth defects in the offspring but found an increase in birth defects in general in the offspring of pregnancies where the mother had taken belladonna. there was no relationship to any particular syndrome of anomalies. a statistically significant (although weak) association was discovered between congenital anomalies and maternal use of belladonna. a study was conducted based on the infants of 554 women who took belladonna during the first four months of pregnancy. the study was conducted in the collaborative perinatal project and showed that belladonna is unlikely to cause minor congenital abnormalities. the estimated maximum risk is most likely less than 3% if maternal belladonna is used early in pregnancy.1 labor or delivery opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. an opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. belladonna and opium suppositories is not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. opioid analgesics, including belladonna and opium suppositories, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. however, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression. risk summary the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for belladonna and opium suppositories and any potential adverse effects on the breastfed infant from belladonna and opium suppositories or from the underlying maternal condition. clinical considerations infants exposed to belladonna and opium suppositories through breast milk should be monitored for excess sedation and respiratory depression. withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped. infertility chronic use of opioids may cause reduced fertility in females and males of reproductive potential. it is not known whether these effects on fertility are reversible [see adverse reactions (6.1)]. the safety and effectiveness of belladonna and opium suppositories in pediatric patients have not been established. elderly patients (aged 65 years or older) may have increased sensitivity to belladonna and opium. in general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. titrate the dosage of belladonna and opium suppositories slowly in geriatric patients [see warnings and precautions (5.2) ]. belladonna and opium suppositories contains opium, a schedule ii controlled substance. belladonna and opium suppositories contains opium, a substance with a high potential for abuse similar to other opioids including fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. belladonna and opium suppositories can be abused and is subject to misuse, addiction, and criminal diversion [see warnings and precautions (5.1) ]. all patients treated with opioids require careful monitoring for signs of abuse and addiction, since use of opioid analgesic products carries the risk of addiction even under appropriate medical use. prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and includes: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal. “drug-seeking” behavior is very common in persons with substance use disorders. drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating health care provider(s). “doctor shopping” (visiting multiple prescribers) to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction. preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control. abuse and addiction are separate and distinct from physical dependence and tolerance. health care providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. in addition, abuse of opioids can occur in the absence of true addiction. belladonna and opium suppositories, like other opioids, can be diverted for non-medical use into illicit channels of distribution. careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised. proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs. risks specific to abuse of belladonna and opium suppositories belladonna and opium suppositories are for rectal use only. abuse of belladonna and opium suppositories poses a risk of overdose and death. the risk is increased with concurrent abuse of belladonna and opium suppositories with alcohol and other central nervous system depressants. parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and hiv. both tolerance and physical dependence can develop during chronic opioid therapy. tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects. physical dependence results in withdrawal symptoms after abrupt discontinuation or a significant dosage reduction of a drug. withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene), mixed agonist/antagonist analgesics (pentazocine, butorphanol, nalbuphine), or partial agonists (buprenorphine). physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage. belladonna and opium suppositories should not be abruptly discontinued [see dosage and administration (2.4) ]. if belladonna and opium suppositories is abruptly discontinued in a physically-dependent patient, a withdrawal syndrome may occur. some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. other signs and symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see use in specific populations (8.1) ].

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), opium (unii: 37m3mz001l) (opium - unii:37m3mz001l) - belladonna and opium suppositories are indicated for the management of ureteral spasm pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1) ], reserve belladonna and opium suppositories for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: risk summary prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome. there are no available data with belladonna and opium suppositories in pregnant women to inform a drug associated risk for major birth defects and miscarriage. clinical considerations fetal/neonatal adverse reactions prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. the onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [see warnings and precautions (5.3) ]. belladonna refers to plant alkaloids that contain anticholinergic agents such as atropine. atropine used in human pregnancies has not been associated with birth defects or adverse fetal effects although the drug readily crosses the placenta. use during pregnancy may increase risk of respiratory abnormalities, hypospadias, and eye or ear malformations but causal relationship is unclear. the collaborative perinatal project found no relationship between first trimester use of atropine and birth defects in the offspring but found an increase in birth defects in general in the offspring of pregnancies where the mother had taken belladonna. there was no relationship to any particular syndrome of anomalies. a statistically significant (although weak) association was discovered between congenital anomalies and maternal use of belladonna. a study was conducted based on the infants of 554 women who took belladonna during the first four months of pregnancy. the study was conducted in the collaborative perinatal project and showed that belladonna is unlikely to cause minor congenital abnormalities. the estimated maximum risk is most likely less than 3% if maternal belladonna is used early in pregnancy.1 labor or delivery opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. an opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. belladonna and opium suppositories is not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. opioid analgesics, including belladonna and opium suppositories, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. however, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression. risk summary the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for belladonna and opium suppositories and any potential adverse effects on the breastfed infant from belladonna and opium suppositories or from the underlying maternal condition. clinical considerations infants exposed to belladonna and opium suppositories through breast milk should be monitored for excess sedation and respiratory depression. withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped. infertility chronic use of opioids may cause reduced fertility in females and males of reproductive potential. it is not known whether these effects on fertility are reversible [see adverse reactions (6.1)]. the safety and effectiveness of belladonna and opium suppositories in pediatric patients have not been established. elderly patients (aged 65 years or older) may have increased sensitivity to belladonna and opium. in general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. titrate the dosage of belladonna and opium suppositories slowly in geriatric patients [see warnings and precautions (5.2) ]. belladonna and opium suppositories contains opium, a schedule ii controlled substance. belladonna and opium suppositories contains opium, a substance with a high potential for abuse similar to other opioids including fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. belladonna and opium suppositories can be abused and is subject to misuse, addiction, and criminal diversion [see warnings and precautions (5.1) ]. all patients treated with opioids require careful monitoring for signs of abuse and addiction, since use of opioid analgesic products carries the risk of addiction even under appropriate medical use. prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and includes: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal. “drug-seeking” behavior is very common in persons with substance use disorders. drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating health care provider(s). “doctor shopping” (visiting multiple prescribers) to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction. preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control. abuse and addiction are separate and distinct from physical dependence and tolerance. health care providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. in addition, abuse of opioids can occur in the absence of true addiction. belladonna and opium suppositories, like other opioids, can be diverted for non-medical use into illicit channels of distribution. careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised. proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs. risks specific to abuse of belladonna and opium suppositories belladonna and opium suppositories are for rectal use only. abuse of belladonna and opium suppositories poses a risk of overdose and death. the risk is increased with concurrent abuse of belladonna and opium suppositories with alcohol and other central nervous system depressants. parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and hiv. both tolerance and physical dependence can develop during chronic opioid therapy. tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects. physical dependence results in withdrawal symptoms after abrupt discontinuation or a significant dosage reduction of a drug. withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene), mixed agonist/antagonist analgesics (pentazocine, butorphanol, nalbuphine), or partial agonists (buprenorphine). physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage. belladonna and opium suppositories should not be abruptly discontinued [see dosage and administration (2.4) ]. if belladonna and opium suppositories is abruptly discontinued in a physically-dependent patient, a withdrawal syndrome may occur. some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. other signs and symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see use in specific populations (8.1) ].

United States - English - NLM (National Library of Medicine)

natural creations, inc. - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), echinacea angustifolia (unii: vb06av5us8) (echinacea angustifolia - unii:vb06av5us8), eupatorium perfoliatum flowering top (unii: 1w0775vx6e) (eupatorium perfoliatum flowering top - unii:1w0775vx6e), gelsemium sempervirens root (unii: 639kr60q1q) (gelsemium sempervirens root - unii:639kr60q1q), lycopodium clavatum spore (unii: c88x29y479) (lycopodium clavatum spore - unii:c88x29y479), phosphoric acid (unii: e4ga8884nn) (phosph - atropa belladonna 30 [hp_x] in 1 ml - uses: temporarily relieves aches, fevers, restlessness.** uses: temporarily relieves aches, fevers, restlessness.**

United States - English - NLM (National Library of Medicine)

natural creations, inc. - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), black cohosh (unii: k73e24s6x9) (black cohosh - unii:k73e24s6x9), lachesis muta venom (unii: vsw71ss07i) (lachesis muta venom - unii:vsw71ss07i), strychnos nux-vomica seed (unii: 269xh13919) (strychnos nux-vomica seed - unii:269xh13919), pulsatilla vulgaris (unii: i76kb35jev) (pulsatilla vulgaris - unii:i76kb35jev), claviceps purpurea sclerotium (unii: 01g9xea93n) (claviceps purpurea sclerotium - unii:01g9xea93n), sepia offici - atropa belladonna 30 [hp_c] in 1 ml - uses: temporarily relieves symptoms associated with menopause, such as lower back pain, hot flashes.** uses: temporarily relieves symptoms associated with menopause, such as lower back pain, hot flashes.**

United States - English - NLM (National Library of Medicine)

legacy pharma inc. - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), opium (unii: 37m3mz001l) (opium - unii:37m3mz001l) - belladonna and opium suppositories are indicated for the management of ureteral spasm pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. belladonna and opium suppositories are used for relief of moderate to severe pain associated with ureteral spasm not responsive to non-narcotic analgesics and to space intervals between injections of opiates.  belladonna and opium suppositories are for rectal use only. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1) ], reserve belladonna and opium suppositories  for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesic not recommended for use in children 12 years of age and under belladonna and opium suppositor

United States - English - NLM (National Library of Medicine)

seroyal usa - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h) - atropa belladonna 3 [hp_x] - indications for the temporary relief of symptoms associated with flu and fever indications for the temporary relief of symptoms associated with flu and fever directions adults: take five granules three times daily or as recommended by your healthcare practitioner. children: take three granules and follow adult directions.

United States - English - NLM (National Library of Medicine)

uriel pharmacy inc - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), apis mellifera (unii: 7s82p3r43z) (apis mellifera - unii:7s82p3r43z) - atropa belladonna 4 [hp_x] - directions: for oral use only. use: temporary relief of fever.

United States - English - NLM (National Library of Medicine)

uriel pharmacy inc. - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), mercurialis perennis (unii: q35465a1ma) (mercurialis perennis - unii:q35465a1ma), calcium sulfide (unii: 1mbw07j51q) (calcium sulfide - unii:1mbw07j51q), lachesis muta venom (unii: vsw71ss07i) (lachesis muta venom - unii:vsw71ss07i) - atropa belladonna 4 [hp_x] in 1 ml - directions: for oral use. use: promotes healing of minor wounds.

United States - English - NLM (National Library of Medicine)

uriel pharmacy inc. - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), apis mellifera (unii: 7s82p3r43z) (apis mellifera - unii:7s82p3r43z) - atropa belladonna 4 [hp_x] in 1 ml - directions: for oral use. use: temporary relief of headache.